{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:11:33Z","timestamp":1790194293254,"version":"4.1.0"},"reference-count":156,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Therapeutics derived from donated blood or its constituents are classifiable into blood components and plasma derivatives. The latter are defined as medicines\/drugs\/pharmaceuticals produced from the industrial fractionation of thousands of pooled plasma donations and characterised with relative precision to a pre-defined specification through sampling of a homogenous pharmaceutical batch. The former are defined as components\/biologicals produced using relatively simple (but increasingly complex) technologies in blood centres from single or small pools of isolated components from whole blood and are pre-specified through regulatory standards with relatively wide limits because of the inherent biologic variability of individual donors. This review discusses the evolution of technology to reduce the risk of pathogen transmission by blood-derived therapeutics, assess the state of the approved technologies for pathogen-reduced blood components, and examine the features of the blood-provider and regulatory framework globally that have shaped, and in some instances impeded, the implementation of component pathogen reduction to an extent equivalent to that achieved for plasma derivatives. The ensuing risks to the public\u2019s confidence in the blood supply are discussed, and remedial actions are proposed. The features of a new paradigm for blood safety are outlined.<\/jats:p>","DOI":"10.3390\/pathogens15040442","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:37:42Z","timestamp":1776677862000},"page":"442","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathogen Reduction of Transfused Blood Components\u2014The End of the Beginning Rather than the Beginning of the End"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0804-7463","authenticated-orcid":false,"given":"Albert","family":"Farrugia","sequence":"first","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, Perth, WA 6009, Australia"},{"name":"International Plasma and Fractionation Association, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-9869","authenticated-orcid":false,"given":"Laurence","family":"Corash","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-4571","authenticated-orcid":false,"given":"Raymond","family":"Goodrich","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3293-7861","authenticated-orcid":false,"given":"Leni","family":"von Bonsdorff","sequence":"additional","affiliation":[{"name":"International Plasma and Fractionation Association, 1066 CX Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/trf.13681","article-title":"Probable transfusion-transmitted Zika virus in Brazil","volume":"56","author":"Angerami","year":"2016","journal-title":"Transfusion"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez-Richarte, \u00c1., Salazar, M.I.O., de Gim\u00e9nez-Richarte, M.P., Collado, M., Fern\u00e1ndez, P.L., Clavijo, C., Navarro, L., Arbona, C., Marco, P., and Ramos-Rincon, J. (2022). Transfusion-transmitted arboviruses: Update and systematic review. PLoS Neglected Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010843"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e29689","DOI":"10.1002\/jmv.29689","article-title":"Dengue virus transmission risk in blood donation: Evidence from Thailand","volume":"96","author":"Limothai","year":"2024","journal-title":"J. Med. Virol."},{"key":"ref_4","first-page":"267","article-title":"Prevalence of Chikungunya, Dengue and Zika viruses in blood donors: A systematic literature review and meta-analysis","volume":"20","author":"Salazar","year":"2022","journal-title":"Blood Transfus."},{"key":"ref_5","first-page":"101089","article-title":"Transfusion-transmitted infections: Risks and mitigation strategies for Oropouche virus and other emerging arboviruses in Latin America and the Caribbean","volume":"46","author":"Tabares","year":"2025","journal-title":"Lancet Reg. Health\u2014Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12985-025-02627-8","article-title":"Incidence and estimated risk of residual transmission of hepatitis a virus and parvovirus B19 by blood transfusion in the state of Rio De Janeiro\u2014Brazil: A retrospective study","volume":"22","author":"Alves","year":"2025","journal-title":"Virol. J."},{"key":"ref_7","first-page":"2406834","article-title":"Assessment of Hepatitis E virus transmission risks: A comprehensive review of cases among blood transfusion recipients and blood donors","volume":"14","author":"Singson","year":"2024","journal-title":"Infect. Ecol. Epidemiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/jpids\/piab083","article-title":"Transfusion-Transmitted Malaria: Two Pediatric Cases From the United States and Their Relevance in an Increasingly Globalized World","volume":"10","author":"Stubbs","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41231-017-0013-9","article-title":"Residual risk of transfusion-transmitted malaria infection in a malaria endemic sub-Saharan African setting","volume":"2","author":"Texier","year":"2017","journal-title":"Transl. Med. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/tme.13101","article-title":"Risk of transfusion-associated malaria in sub-Saharan Africa: The case of Mali","volume":"34","author":"Loua","year":"2024","journal-title":"Transfus. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103734","DOI":"10.1016\/j.htct.2025.103734","article-title":"Transmitted blood infections and emerging vector-borne diseases in blood donors in northern Portugal","volume":"47","author":"Mota","year":"2025","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"da Gama, A.N.S., and Soeiro, M.d.N.C. (2025). Trypanosoma cruzi Transmission Through Blood Samples and Derivatives: Main Routes, Control Strategies, and Recent Advancements in Blood Banks. Pathogens, 14.","DOI":"10.3390\/pathogens14020133"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/vox.13735","article-title":"The prevalence of hepatitis B virus, human T-lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa","volume":"119","author":"Willemse","year":"2024","journal-title":"Vox Sang."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ahmed, W., Ahmed, I., Bhanbhro, F., Kerio, A., Ali, A., Ali, S., and Wassan, P. (2025). Frequency of pediatric HIV infection among high-risk children admitted to a tertiary care hospital at Sukkur, Sindh, Pakistan. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-11256-z"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kanyike, A.M., Kakuba, F., Mayambala, P., Nalunkuma, R., Nakandi, R.M., Mulumba, Y., Namulema, E., Nsingo, S., and Ssebuufu, R. (2025). Prevalence trends of transfusion-transmitted infections at a tertiary private hospital blood bank in Uganda: A retrospective 6-year review (2017\u20132022). BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10882-x"},{"key":"ref_16","unstructured":"Yawitch, T., Davison, K., Harvala, H., and Brailsford, S. (2026, April 17). Serious Hazards of Transfusion (SHOT)\u2014UK. Transfusion-Transmitted Infections [Internet]. Report No. Available online: https:\/\/www.shotuk.org\/wp-content\/uploads\/2024\/10\/21.-Transfusion-Transmitted-Infections-TTI-2023-1.pdf."},{"key":"ref_17","unstructured":"(2026, April 17). Europeancommission Haemovigilance Annual Sare Report 2024 [Internet]. 2024. Report No. Available online: https:\/\/health.ec.europa.eu\/document\/download\/880489d2-02cb-471f-92d5-289c534d9f42_en?filename=2024_sare_blood_summary_en.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM197108192850803","article-title":"Bacterial proliferation in platelet products stored at room temperature. Transfusion-induced Enterobacter sepsis","volume":"285","author":"Buchholz","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2003.1.575","article-title":"Bacterial Contamination of Blood Components: Risks, Strategies, and Regulation: Joint ASH and AABB Educational Session in Transfusion Medicine","volume":"2003","author":"Hillyer","year":"2003","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Damgaard, C., Magnussen, K., Enevold, C., Nilsson, M., Tolker-Nielsen, T., Holmstrup, P., and Nielsen, C. (2015). Viable bacteria associated with red blood cells and plasma in freshly drawn blood donations. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120826"},{"key":"ref_22","first-page":"376","article-title":"Periodontitis increases risk of viable bacteria in freshly drawn blood donations","volume":"19","author":"Damgaard","year":"2021","journal-title":"Blood Transfus."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Farrugia, A. (2023). The Evolution of the Safety of Plasma Products from Pathogen Transmission\u2014A Continuing Narrative. Pathogens, 12.","DOI":"10.3390\/pathogens12020318"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Farrugia, A. (2025). Pathogen Safety Issues Around the \u2018Blood Scandals\u2019 1995-2024-A Perspective Built on Experience. Pathogens, 14.","DOI":"10.3390\/pathogens14090868"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101849","DOI":"10.1016\/j.biologicals.2025.101849","article-title":"The past, present and future of blood plasma fractionation","volume":"91","author":"Curling","year":"2025","journal-title":"Biologicals"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/j.1537-2995.2010.02851.x","article-title":"Transfusion-associated infections: 50 years of relentless challenges and remarkable progress","volume":"50","author":"Perkins","year":"2010","journal-title":"Transfusion"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0887-7963(91)70190-9","article-title":"Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma","volume":"5","author":"Wagner","year":"1991","journal-title":"Transfus. Med. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/trf.18398","article-title":"Incidence and window period residual risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2017 to 2023: The transfusion-transmissible infections monitoring system","volume":"65","author":"Huseynova","year":"2025","journal-title":"Transfusion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/vox.13592","article-title":"International review of blood donation nucleic acid amplification testing","volume":"119","author":"Faddy","year":"2024","journal-title":"Vox Sang."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2008-07-077370","article-title":"The hazards of blood transfusion in historical perspective","volume":"112","author":"Alter","year":"2008","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/vox.13740","article-title":"Introduction of 7-day amotosalen\/ultraviolet A light pathogen-reduced platelets in Honduras: Impact on platelet availability in a lower middle-income country","volume":"119","author":"Pedraza","year":"2024","journal-title":"Vox Sang."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rebulla, P., and Prati, D. (2022). Pathogen Reduction for Platelets-A Review of Recent Implementation Strategies. Pathogens, 11.","DOI":"10.3390\/pathogens11020142"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Piccin, A., Allameddine, A., Spizzo, G., Lappin, K.M., and Prati, D. (2024). Platelet Pathogen Reduction Technology\u2014Should We Stay or Should We Go\u2026?. J. Clin. Med., 13.","DOI":"10.20944\/preprints202407.1600.v1"},{"key":"ref_34","first-page":"7","article-title":"Pathogen inactivation of red cell concentrates and whole blood: I. History, technologies and in vitro product preservation studies","volume":"121","author":"Cancelas","year":"2025","journal-title":"Vox Sang."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44361-025-00013-1","article-title":"Advances in pathogen reduction technologies: Enhancing safety and functionality of blood products","volume":"12","author":"Arbaeen","year":"2026","journal-title":"J. Umm Al-Qura Univ. Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1111\/j.1537-2995.2012.03622.x","article-title":"Plasma components: Properties, differences, and uses","volume":"52","author":"Benjamin","year":"2012","journal-title":"Transfusion"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ajcp\/aqae073","article-title":"Implementation and early outcomes with Pathogen Reduced Cryoprecipitated Fibrinogen Complex","volume":"162","author":"Sethapati","year":"2024","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2516.2008.01797.x","article-title":"Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems","volume":"14","author":"Burnouf","year":"2008","journal-title":"Haemophilia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/trf.17836","article-title":"Thirty years of experience with solvent\/detergent-treated plasma for transfusion medicine","volume":"64","author":"Cushing","year":"2024","journal-title":"Transfusion"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/ALN.0000000000005716","article-title":"Transfusion of Amustaline\/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial","volume":"143","author":"Sekela","year":"2025","journal-title":"Anesthesiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/voxs.12524","article-title":"Progress towards an appropriate pathogen reduction technology for whole blood in Africa","volume":"15","author":"Lanteri","year":"2020","journal-title":"ISBT Sci. Ser."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(16)00581-X","article-title":"Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: The African Investigation of the Mirasol System (AIMS) randomised controlled trial","volume":"387","author":"Allain","year":"2016","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/trf.18484","article-title":"Effects of an amustaline (S-303)\/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood","volume":"66","author":"Khoshi","year":"2025","journal-title":"Transfusion"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sherstyukova, E., Semenova, J., Kandrashina, S., Bogdanova, A., Vinogradov, I., Inozemtsev, V., Shvedov, M., Grechko, A., Dokukin, M., and Kuzovlev, A. (2025). Pathogen-Reduced Low-Titer Group O Whole Blood for Managing Massive Blood Loss in Prehospital and Early Hospital Settings: An In Vitro Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14176292"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13063-022-06137-8","article-title":"The Mirasol Evaluation of Reduction in Infections Trial (MERIT): Study protocol for a randomized controlled clinical trial","volume":"23","author":"Kasirye","year":"2022","journal-title":"Trials"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tmrv.2005.02.004","article-title":"The Current Status and Potential Role of Laboratory Testing to Prevent Transfusion-Transmitted Malaria","volume":"19","author":"Seed","year":"2005","journal-title":"Transfus. Med. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.1993.tb02507.x","article-title":"Chagas\u2019 disease and blood transfusion: A New World problem?","volume":"64","author":"Wendel","year":"1993","journal-title":"Vox Sang."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1537-2995.1988.28188127955.x","article-title":"Prevalence of Babesia antibody in a selected blood donor population","volume":"28","author":"Popovsky","year":"1988","journal-title":"Transfusion"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1046\/j.1537-2995.2003.00481.x","article-title":"West Nile virus infection transmitted by blood transfusion","volume":"43","author":"Harrington","year":"2003","journal-title":"Transfusion"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMc0708673","article-title":"Transfusion-Transmitted Dengue Infection Study Group. Dengue hemorrhagic fever transmitted by blood transfusion","volume":"359","author":"Tambyah","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1537-2995.2004.03300.x","article-title":"Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan","volume":"44","author":"Matsubayashi","year":"2004","journal-title":"Transfusion"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2008.10.004","article-title":"Globalisation and blood safety","volume":"23","author":"Farrugia","year":"2009","journal-title":"Blood Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253ps10","DOI":"10.1126\/scitranslmed.3009872","article-title":"Emerging Viral Diseases: Confronting Threats with New Technologies","volume":"6","author":"Marston","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schuffenecker, I., Iteman, I., Michault, A., Murri, S., Frangeul, L., Vaney, M.C., Lavenir, R., Pardigon, N., Reynes, J.M., and Pettinelli, F. (2006). Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030263"},{"key":"ref_55","unstructured":"Fauci, A. (2026, April 17). Global Examples of Emerging and Re-Emerging Infectious Diseases, Available online: https:\/\/www.niaid.nih.gov\/sites\/default\/files\/main%20map.jpg."},{"key":"ref_56","unstructured":"World Health Organisation (2026, April 07). WHO Recommendations on SARS and Blood Safety 2021. Available online: https:\/\/www.who.int\/publications\/m\/item\/who-recommendations-on-sars-and-blood-safety."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/trf.15620","article-title":"West Nile virus activity in United States blood donors and optimizing detection strategies: 2014\u20132018","volume":"60","author":"Groves","year":"2020","journal-title":"Transfusion"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e2524494","DOI":"10.1001\/jamanetworkopen.2025.24494","article-title":"Blood Donation Screening and West Nile Virus Surveillance Strategy in France","volume":"8","author":"Grard","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/trf.18326","article-title":"West Nile Virus positivity amongst Canadian blood donors and effectiveness of off-season screening","volume":"65","author":"Charlton","year":"2025","journal-title":"Transfusion"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1537-2995.2010.02989.x","article-title":"Donor Return Following Temporary Deferral","volume":"51","author":"Custer","year":"2011","journal-title":"Transfusion"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tracli.2024.04.002","article-title":"The return rate of deferred blood donors in Iran","volume":"31","author":"Maghsudlu","year":"2024","journal-title":"Transfus. Clin. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1537-2995.2009.02111.x","article-title":"Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La R\u00e9union","volume":"49","author":"Simon","year":"2009","journal-title":"Transfusion"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1111\/trf.14892","article-title":"Emergency response of four transfusion centers during the last Chikungunya outbreak in Italy","volume":"58","author":"Pierelli","year":"2018","journal-title":"Transfusion"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1056\/NEJM195111152452003","article-title":"Fatal transfusion reactions from massive bacterial contamination of blood","volume":"245","author":"Borden","year":"1951","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.7326\/0003-4819-39-6-1228","article-title":"Fatal transfusion reactions from contamination of stored blood by cold growing bacteria","volume":"39","author":"Stevens","year":"1953","journal-title":"Ann. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0887-7963(91)70194-6","article-title":"Blood Product-Associated Bacterial Sepsis","volume":"5","author":"Goldman","year":"1991","journal-title":"Transfus. Med. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1537-2995.1990.30790385515.x","article-title":"Reports of 355 transfusion-associated deaths: 1976 through 1985","volume":"30","author":"Sazama","year":"1990","journal-title":"Transfusion"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Jacobs, M.R., Zhou, B., Tayal, A., and Maitta, R.W. (2024). Bacterial Contamination of Platelet Products. Microorganisms, 12.","DOI":"10.3390\/microorganisms12020258"},{"key":"ref_69","unstructured":"Yawitch, T., Davison, K., and Brailsford, S. (2026, April 17). Severe hazards of Transfusion (SHOT) UK\u2014Transfusion-Transmitted Infections [Internet]. 2024. Report No. Available online: https:\/\/www.shotuk.org\/wp-content\/uploads\/2025\/07\/23.-Transfusion-Transmitted-Infections-TTI-2024.pdf."},{"key":"ref_70","first-page":"433","article-title":"Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: An expert opinion from the European Centre for Disease Prevention and Control consultation meeting","volume":"17","author":"Compernolle","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Solari, D., Serricchio, M., Motta, M., Widmer, N., Stolz, M., Gowland, P., Niederhauser, C., and Fontana, S. (2025). Parvovirus B19 Infection after Transfusion of a Pathogen-Reduced Platelet Concentrate: A Case Report. Transfus. Med. Hemother.","DOI":"10.1159\/000548745"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Laperche, S., de la Taille, V., Gallian, P., Pouchol, E., Humbrecht, C., Montembault, A., Asso-Bonnet, M., Le Cam, S., Peyrard, T., and Tiberghien, P. (2026). Pathogen-reduced platelet concentrates in France: Impact on the risk of transfusion-transmitted infections, 2017\u20132024. Vox Sang.","DOI":"10.1111\/vox.70199"},{"key":"ref_73","unstructured":"Centers for Disease Control and Prevention (CDC) (2010). HIV transmission through transfusion\u2014Missouri and Colorado, 2008. MMWR Morb. Mortal. Wkly. Rep., 59, 1335\u20131339."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Akhtar, S., Nasir, J.A., and Hinde, A. (2020). The prevalence of hepatitis C virus infection in \u03b2-thalassemia patients in Pakistan: A systematic review and meta-analysis. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-8414-5"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Abdella, S., Berheto, T.M., Tolera, G., Belete, W., Deressa, T., Feleke, A., H\/Silassie, A., Gezahegn, N., Tadesse, D., and Tefera, M. (2020). Sero-prevalence of transfusion transmittable infections: HIV, Hepatitis B, C and Treponema pallidum and associated factors among blood donors in Ethiopia: A retrospective study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241086"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Peliganga, L.B., Mello, V.M., Sousa, P.S.F., de Horta, M.A.P., Soares, \u00c1.D., Nunes, J.P.d.S., Nobrega, M., and Lewis-Ximenez, L.L. (2021). Transfusion Transmissible Infections in Blood Donors in the Province of Bi\u00e9, Angola, during a 15-Year Follow-Up, Imply the Need for Pathogen Reduction Technologies. Pathogens, 10.","DOI":"10.3390\/pathogens10121633"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/vox.70102","article-title":"Seroprevalence of transfusion-transmitted infections among blood donors in India: A systematic review and meta-analysis","volume":"120","author":"Golia","year":"2025","journal-title":"Vox Sang."},{"key":"ref_78","unstructured":"(2026, April 07). Guidelines on Estimation of Residual Risk of HIV, HBV or HCV Infections via Cellular Blood Components and Plasma. Available online: https:\/\/www.who.int\/publications\/m\/item\/annex-4-trs-no-1004."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tracli.2015.11.001","article-title":"Diop, \u00c9valuation de l\u2019efficacit\u00e9 de la s\u00e9lection m\u00e9dicale des donneurs de sang dans la pr\u00e9vention des agents infectieux","volume":"23","author":"MSeck","year":"2016","journal-title":"Transfus. Clin. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12936-024-04966-3","article-title":"Screening blood donors for malaria, can we increase the number of eligible donors? An observational retrospective study","volume":"23","author":"Norman","year":"2024","journal-title":"Malar. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/trf.17981","article-title":"Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study","volume":"64","author":"Domingue","year":"2024","journal-title":"Transfusion"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/vox.13272","article-title":"ISBT Transfusion-Transmitted Infectious Diseases Working Party, Subgroup on Bacteria. Residual risks of bacterial contamination for pathogen-reduced platelet components","volume":"117","author":"Cloutier","year":"2022","journal-title":"Vox Sang."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.techfore.2008.09.002","article-title":"Leapfrogging in mobile telephony: A measure for comparing country performance","volume":"76","author":"James","year":"2009","journal-title":"Technol. Forecast. Soc. Change"},{"key":"ref_84","unstructured":"Ritchie, H. (2026, January 12). Many Countries Are \u201cLeapfrogging\u201d Landlines and Going Straight to Mobile Phones [Internet]. Available online: https:\/\/ourworldindata.org\/data-insights\/many-countries-are-leapfrogging-landlines-and-going-straight-to-mobile-phones."},{"key":"ref_85","unstructured":"Bhattacharya, S., and Hellermann, P. (2026, January 13). How Technology Leapfrogging Creates Unexpected Market Opportunities|Foundamental [Internet]. Available online: https:\/\/www.foundamental.com\/perspectives\/how-technology-leapfrogging-creates-unexpected-market-opportunities."},{"key":"ref_86","unstructured":"Sharma, S. (2025, December 08). Alarm in India After Children Contract HIV from Contaminated Blood. The Independent [Internet]. Available online: https:\/\/www.independent.co.uk\/asia\/india\/hiv-positive-blood-transfusion-thalassemia-madhya-pradesh-b2855957.html."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/trf.16926","article-title":"Cost-effectiveness of pathogen reduction technology for plasma and platelets in Qu\u00e9bec: A focus on potential emerging pathogens","volume":"62","author":"Delage","year":"2022","journal-title":"Transfusion"},{"key":"ref_88","unstructured":"Centers for Disease Control and Prevention (CDC) (2009). West Nile virus transmission via organ transplantation and blood transfusion\u2014Louisiana, 2008. MMWR Morb. Mortal. Wkly. Rep., 58, 1263\u20131267."},{"key":"ref_89","unstructured":"Centers for Disease Control and Prevention (CDC) (2013). Fatal West Nile virus infection after probable transfusion-associated transmission--Colorado, 2012. MMWR Morb. Mortal. Wkly. Rep., 62, 622\u2013624."},{"key":"ref_90","unstructured":"US Pharmacopeia (2026, January 13). Virus Testing of Human Plasma for Further Manufacture. In. 2017. Available online: https:\/\/www.drugfuture.com\/Pharmacopoeia\/usp38\/data\/v38332\/usp38nf33s2_c1240.html#google_vignette."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1537-2995.2003.00496.x","article-title":"West Nile virus and the safety of plasma derivatives: Verification of high safety margins, and the validity of predictions based on model virus data","volume":"43","author":"Kreil","year":"2003","journal-title":"Transfusion"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3201\/eid1510.081668","article-title":"West Nile Virus Infection in Plasma of Blood and Plasma Donors, United States","volume":"15","author":"Planitzer","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V128.22.3844.3844","article-title":"Treatment Use Study of Platelet Components Treated with Amotosalen and Ultraviolet a Light in Response to Emerging Arboviruses in Puerto Rico\u2014True Study Final Results","volume":"128","author":"Rico","year":"2016","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejim.2020.05.019","article-title":"Why should we use convalescent plasma for COVID-19?","volume":"77","author":"Franchini","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/voxs.12093","article-title":"Risk reduction strategies for transfusion-transmissible arboviral infections","volume":"9","author":"Seed","year":"2014","journal-title":"ISBT Sci. Ser."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Ribeiro Mde, O., Arruda, M.B., Calazans, A.R., Frederico, A.V., Brito, A.F., Barreto, B.V.d.S., Brand\u00e3o, E.M., Athayde, H., Nascimento, K.C., and Souza, P. (2025). Detecting Arboviruses Through Screening Asymptomatic Blood Donors in Rio de Janeiro\/Brazil During a Dengue Outbreak. Viruses, 17.","DOI":"10.3390\/v17020224"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/trf.16950","article-title":"Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction","volume":"62","author":"Stramer","year":"2022","journal-title":"Transfusion"},{"key":"ref_98","unstructured":"United States Food and Drug Administration (2026, January 14). Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers [Internet], Available online: https:\/\/www.fda.gov\/media\/153786\/download#:~:text=Can%20pathogen%20reduction%20using%20the%20INTERCEPT%C2%AE%20Blood,of%20transfusion%2Dassociated%20graft%20versus%20host%20disease%20(TA%2DGVHD)."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1111\/trf.15551","article-title":"Do deferred donors continue their donations? A large-scale register study on whole blood donor return in the Netherlands","volume":"59","author":"Spekman","year":"2019","journal-title":"Transfusion"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2011.08635.x","article-title":"A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion","volume":"153","author":"Lozano","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1111\/trf.15511","article-title":"Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days","volume":"59","author":"Infanti","year":"2019","journal-title":"Transfusion"},{"key":"ref_103","unstructured":"Marafon, J.P.R.S., Isola, H., Somme, S., and Maitre, B. (2026). Impact of platelet storage time on transfusion-related adverse reactions: A French hemovigilance study. Transfus. Clin. Biol."},{"key":"ref_104","unstructured":"European Directorate for the Quality of Medicines & HealthCare (2026, April 08). Guide to the Preparation, Use and Quality Assurance of Blood Components-21st Edition. Available online: https:\/\/www.edqm.eu\/en\/blood-guide."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"150875","DOI":"10.1016\/j.tmrv.2025.150875","article-title":"Platelet Additive Solutions and Pathogen Reduction Impact on Transfusion Safety, Patient Management and Platelet Supply","volume":"39","author":"Andreu","year":"2025","journal-title":"Transfus. Med. Rev."},{"key":"ref_106","first-page":"e44148","article-title":"Transfusion-Associated Graft-Versus-Host Disease in Adults","volume":"15","author":"Elmakki","year":"2023","journal-title":"Cureus"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103404","DOI":"10.1016\/j.transci.2022.103404","article-title":"Is pathogen reduction an acceptable alternative to irradiation for risk mitigation of transfusion-associated graft versus host disease?","volume":"61","author":"Li","year":"2022","journal-title":"Transfus. Apher. Sci."},{"key":"ref_108","first-page":"130","article-title":"Pathogen reduced red blood cells as an alternative to irradiated and washed components with potential for up to 42 days storage: Pathogen reduced red blood cells","volume":"22","author":"Larsson","year":"2024","journal-title":"Blood Transfus."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"104088","DOI":"10.1016\/j.transci.2025.104088","article-title":"Pathogen-reduction technology, good in more than one way for cellular blood components, is replacing irradiation","volume":"64","author":"Flegel","year":"2025","journal-title":"Transfus. Apher. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.1994.03520150078041","article-title":"Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply","volume":"272","author":"AuBuchon","year":"1994","journal-title":"JAMA"},{"key":"ref_111","first-page":"211","article-title":"Cost-effectiveness of new blood safety technologies","volume":"102","author":"AuBuchon","year":"2000","journal-title":"Dev. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1423-0410.2002.00198.x","article-title":"Pharmaco-economics of blood transfusion safety: Review of the available evidence","volume":"83","author":"Staginnus","year":"2002","journal-title":"Vox Sang."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1537-2995.2003.00392.x","article-title":"The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations","volume":"43","author":"Jackson","year":"2003","journal-title":"Transfusion"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1537-2995.2006.00828.x","article-title":"Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands","volume":"46","author":"Janssen","year":"2006","journal-title":"Transfusion"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1537-2995.2010.02704.x","article-title":"The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model","volume":"50","author":"Custer","year":"2010","journal-title":"Transfusion"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40258-020-00612-6","article-title":"Economic Analyses of Pathogen-Reduction Technologies in Blood Transfusion: A Systematic Literature Review","volume":"19","author":"LaFontaine","year":"2021","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1111\/trf.16704","article-title":"Cost-effectiveness and budget impact of whole blood pathogen reduction in Ghana","volume":"61","author":"Russell","year":"2021","journal-title":"Transfusion"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s41669-023-00427-w","article-title":"Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review","volume":"7","author":"Laermans","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/trf.16184","article-title":"Buffy coat platelets coming to America: Are we ready?","volume":"61","author":"Gammon","year":"2021","journal-title":"Transfusion"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.transci.2019.06.004","article-title":"The plasma supply in France","volume":"58","author":"Garraud","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_121","unstructured":"Isola, H., Galvanin, A., Pissenem Rudwill, F., Haas, D., Koll, A., Parentin, V., Celia, F., and Kientz, D. (2026, April 17). Amotosalen\/UVA Light Pathogen Reduced Pooled Plasma Stored Frozen for 3\u2009Years and Liquid for 5\u2009Days [Poster] [Internet]. Poster Presented at: 38th International Congress of the ISBT. 2024 June 23. Available online: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13652."},{"key":"ref_122","unstructured":"Cerus Corporation (2026, January 15). Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update [Internet]. Available online: https:\/\/ir.cerus.com\/press-releases\/press-releases-details\/2025\/Cerus-Corporation-Provides-INTERCEPT-Red-Blood-Cell-CE-Mark-Application-Update\/default.aspx."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/trf.18115","article-title":"Quantifying the impact of a novel virus on the economic value of pathogen reduction technology for platelets","volume":"65","author":"Irving","year":"2025","journal-title":"Transfusion"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(25)01431-X","article-title":"What price for increasing blood safety?","volume":"406","author":"Neuberger","year":"2025","journal-title":"Lancet"},{"key":"ref_125","unstructured":"Langstaff, B. (2026, January 16). The Infected Blood Inquiry in the UK\u2014Final Report\u2014Volume 1\u2014Overview and Recommendations [Internet]. UK Government; 2024. Report No. Available online: https:\/\/www.infectedbloodinquiry.org.uk\/sites\/default\/files\/Volume_1.pdf."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.284.2.238","article-title":"Will Blood Transfusion Ever Be Safe Enough?","volume":"284","author":"Klein","year":"2000","journal-title":"JAMA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jval.2020.06.008","article-title":"Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment","volume":"23","author":"Wolff","year":"2020","journal-title":"Value Health"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"100130","DOI":"10.1016\/j.hpopen.2024.100130","article-title":"Patient\u2019s willingness to pay for improved community health insurance in Tanzania","volume":"7","author":"Tani","year":"2024","journal-title":"Health Policy Open"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/hsc.12650","article-title":"Comparison of the demographic and social profile of blood donors and nondonors in Brazil","volume":"27","author":"Zucoloto","year":"2019","journal-title":"Health Soc. Care Community"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/vox.12158","article-title":"Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma","volume":"107","author":"Kwon","year":"2014","journal-title":"Vox Sang."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/vox.13574","article-title":"Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections","volume":"119","author":"Richard","year":"2024","journal-title":"Vox Sang."},{"key":"ref_132","unstructured":"United States Food and Drug Administration (2026, January 15). INTERCEPT\u00ae Blood System for Platelets [Internet], Available online: https:\/\/www.fda.gov\/media\/90089\/download."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/trf.12686","article-title":"Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system","volume":"54","author":"Owada","year":"2014","journal-title":"Transfusion"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"150747","DOI":"10.1016\/j.tmrv.2023.150747","article-title":"Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products: A Narrative Review of Observed and Modeled Risks","volume":"37","author":"Rochette","year":"2023","journal-title":"Transfus. Med. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1046\/j.1537-2995.1996.36996420751.x","article-title":"Considerations of pool size in the manufacture of plasma derivatives","volume":"36","author":"Lynch","year":"1996","journal-title":"Transfusion"},{"key":"ref_136","unstructured":"Leveton, L.B., Sox, H.C., and Stoto, M.A. (2024, March 21). Committee to Study HIV Transmission Through Blood and Blood Products, HIV and the Blood Supply: An Analysis of Crisis Decisionmaking [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232417\/."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/trf.14260","article-title":"Effect of solvent\/detergent-treated pooled plasma on fibrinolysis in reconstituted whole blood","volume":"57","author":"Saadah","year":"2017","journal-title":"Transfusion"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.biologicals.2009.10.019","article-title":"Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Special Section: Advances in Transfusion Safety (pp. 1\u2013104)","volume":"38","author":"Mufti","year":"2010","journal-title":"Biologicals"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.transci.2011.06.006","article-title":"Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates","volume":"45","author":"Seghatchian","year":"2011","journal-title":"Transfus. Apher. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/MOH.0b013e3282e9a433","article-title":"It is time to bring back solvent\u2013detergent plasma","volume":"14","author":"Sandler","year":"2007","journal-title":"Curr. Opin. Hematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1537-2995.2005.00583.x","article-title":"Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: A Phase III clinical trial in cardiac surgery patients","volume":"45","author":"Benjamin","year":"2005","journal-title":"Transfusion"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/trf.18117","article-title":"Characterizing the antibody response to amustaline\/glutathione pathogen-reduced red blood cells","volume":"65","author":"Karim","year":"2025","journal-title":"Transfusion"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/trf.15965","article-title":"Prevalence of natural and acquired antibodies to amustaline\/glutathione pathogen reduced red blood cells","volume":"60","author":"Geisen","year":"2020","journal-title":"Transfusion"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/trf.18245","article-title":"A novel acridine flow cytometry marker to track post-transfusion amustaline\/glutathione pathogen-reduced red blood cell survival in sickle cell disease patients","volume":"65","author":"Benjamin","year":"2025","journal-title":"Transfusion"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Pati, I., Masiello, F., Pupella, S., Cruciani, M., and De Angelis, V. (2022). Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs. Pathogens, 11.","DOI":"10.3390\/pathogens11060639"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/bloodadvances.2023012425","article-title":"Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components","volume":"8","author":"Wheeler","year":"2024","journal-title":"Blood Adv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0268-960X(98)90021-2","article-title":"Neoantigens and antibodies to factor VIII","volume":"12","author":"Prowse","year":"1998","journal-title":"Blood Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.1987.tb04151.x","article-title":"Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs","volume":"65","author":"Littlewood","year":"1987","journal-title":"Br. J. Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.xphs.2022.03.005","article-title":"Therapeutic solutions of human albumin\u2014The possible effect of process-induced molecular alterations on clinical efficacy and safety","volume":"111","author":"Farrugia","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Lopez, E., Scott, N.E., Wines, B.D., Hogarth, P.M., Wheatley, A.K., Kent, S.J., and Chung, A.W. (2019). Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fc\u03b3 Receptors: Implications for Measuring Fc Dependent Antibody Functions. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02415"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1126\/science.1237825","article-title":"Quantifying Long-Term Scientific Impact","volume":"342","author":"Wang","year":"2013","journal-title":"Science"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"042309","DOI":"10.1103\/PhysRevE.95.042309","article-title":"Fame and obsolescence: Disentangling growth and aging dynamics of patent citations","volume":"95","author":"Higham","year":"2017","journal-title":"Phys. Rev. E"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41562-018-0474-5","article-title":"The universal decay of collective memory and attention","volume":"3","author":"Candia","year":"2019","journal-title":"Nat. Hum. Behav."},{"key":"ref_154","unstructured":"Nepomnyashchiy, L., Muyombo, T., Subah, O., and Ishtiaq, A. (2026, February 22). The Neglected Crisis in Safe Blood Access. Think Global Health [Internet]. Available online: https:\/\/www.thinkglobalhealth.org\/article\/neglected-crisis-safe-blood-access."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000057291","article-title":"Disease transmission by blood products: Past, present and future","volume":"32","author":"Murphy","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Farrugia, A., and Quinti, I. (2014). Manufacture of immunoglobulin products for patients with primary antibody deficiencies\u2014The effect of processing conditions on product safety and efficacy. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00665"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/4\/442\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:14:18Z","timestamp":1776680058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/4\/442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":156,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pathogens15040442"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15040442","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}